Skip to main content

Table 2 Adverse events for each agent

From: Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia

Type of agents Agents Adverse events
γ-Secretase inhibitors (GSIs) MK-0752 Gastrointestinal toxicity (mainly diarrhea)
PF-03084014 Nausea and vomiting
BMS-906024 Tolerable gastrointestinal toxicity
MRK-560 Did not show obvious gastrointestinal pathological changes and thymus T cell development defects
ADAM inhibitors G1254023X No records of adverse events related to the drug found in the literature
Monoclonal antibody targeting NOTCH1 OMP-52M51 May be resistant to T-ALL of carried two activation mutations of NOTCH1 gene: p.Q1584H and p.L1585P
mAb604.107 No records of adverse events related to the drug found in the literature
Direct inhibition of NOTCH1 transcription factor complex SAHM1 No records of adverse events related to the drug found in the literature
SERCA inhibitors Thapsigargicin Severe dose-limited cardiotoxicit
JQ-FT Complex process and poor practicality
Clerodane diterpene casearin J (CJ) No records of adverse events related to the drug found in the literature
CAD204520 No weight loss, no adverse effects on behavior, and no signs of acute cardiotoxicity or gastrointestinal metaplasia